Industry Leader articles are written by executives at biopharma companies, consultancies, research firms, and companies that provide services or products to sponsors. The topics are nonpromotional and focused on industrywide business issues.
With the right preparation and investments, entering the federal government market can lead to considerable growth and visibility for your company. Consider the following tips for increased chances of success.
The medical device market is about to succumb to a raft of substantial international regulatory changes, starting with Europe’s MDR in May 2020, as public pressure and industry authorities call for greater accountability for patient safety.
Typically, there are two paths biotechs take when going public — seeking VC funding or raising capital via a reverse merger. However, INmune Bio chose a third path.
Much like in many other areas of the drug development continuum, the focus now in the cold chain is on data and how it can be unlocked and analyzed in real time to save money, time, and resources — while also better ensuring patient safety.
As the industry’s appetite for creating and using data-driven insights to improve clinical outcomes continues to grow, so does the need to integrate and validate disparate data sources. Efforts to impose greater consistency and rigor should be welcomed by all.
Life science leaders must balance their need to apply AI technologies to improve patient care, and bottom lines — without getting caught-up in the AI hype machine.
Let’s face it … pitching potential investors is a remarkable opportunity. It could be your one shot at getting your idea or company off the ground, so you better be appealing, tantalizing, and even provocative.
Women who are starting life sciences companies often do not have access to a network of mentors and advisors, whose strong advocacy establishes instant credibility and opens the doors to investors.
Here are some examples of why “soft skills,” such as those related to relationship building, leadership, and communication, are essential to today’s pharma and biotech leaders.
Companies frequently talk about being patient-centric. But what I don’t hear discussed as often is the role of the patient after a drug is approved. And I am convinced it is equally important. Why? Because patients are not static; they grow and change over time.
Pfizer’s top scientist, Mikael Dolsten, M.D., Ph.D., talks about being hyper focused during company’s R&D turnaround amongst CEO turnover, company integrations and M&A.
Robert Hariri, M.D., Ph.D., discusses how he became friends with life coach Tony Robbins, and why Robbins decided to invest in his company.
A preview of an October 2109 issue article that discusses the results of the 2018 MassNextGen initiative that provides funding and coaching support to early-stage life sciences companies started by females.
Chief Editor Rob Wright discusses the implications of the recent Gallup poll indicating pharma presently being the most poorly regarded of all industries in the eyes of Americans.
Chief Editor Rob Wright saw glimpses into the impending opioid crisis back when he was working as a pharma sales rep in the pain management space.